Eisai and Biogen to Continue Phase 2 Alzheimer’s Therapy Trial for Six More Months
News
Eisai and Biogen had hoped that using an advanced statistical method to analyze Phase 2 clinical trial results would show at 12 months rather than the normal 18 that their Alzheimer’s ... Read more